19845-24-0 Usage
General Description
1-Methyl-6,7-diphenylulazine is a chemical compound with the molecular formula C20H17N3. It is a lumazine derivative, which is a type of heterocyclic compound containing a pyrazine ring fused to a benzene ring. 1-Methyl-6,7-diphenyllumazine has potential applications in organic synthesis and as a building block in the development of new materials. It has been studied for its potential use in the field of organic electronics due to its unique electronic properties. Additionally, 1-Methyl-6,7-diphenylulazine has been investigated for its potential biological activities, including potential anti-tumor and anti-inflammatory properties. Overall, this compound has shown promise for a range of applications and continues to be of interest in scientific research.
Check Digit Verification of cas no
The CAS Registry Mumber 19845-24-0 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 1,9,8,4 and 5 respectively; the second part has 2 digits, 2 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 19845-24:
(7*1)+(6*9)+(5*8)+(4*4)+(3*5)+(2*2)+(1*4)=140
140 % 10 = 0
So 19845-24-0 is a valid CAS Registry Number.
InChI:InChI=1/C19H14N4O2/c1-23-17-16(18(24)22-19(23)25)20-14(12-8-4-2-5-9-12)15(21-17)13-10-6-3-7-11-13/h2-11H,1H3,(H,22,24,25)
19845-24-0Relevant articles and documents
Immunosuppressive effects of pteridine derivatives
-
, (2008/06/13)
Novel poly-substituted pteridinediones (lumazines), and mono- or polysubstituted 2-thiolumazines, 4-thiolumazines or 2,4-dithiolumazines, having disclosed substituents in positions 1, 3, 6 and 7 of the pteridine ring, and pharmaceutically acceptable salts thereof, being represented by the general formula (I). are useful as biologically active ingredients in preparing pharmaceutical compositions especially for the treatment or prevention of a CNS disorder, a cell proliferative disorder, a viral infection, an immune or auto-immune disorder or a transplant rejection. Combinations of the pteridine derivatives of the invention with an immunosuppressant or immunomodulator drug, an antineoplastic drug or an antiviral agent, providing potential synergistic effects, are also disclosed.